Skip to main content
Erschienen in: Japanese Journal of Ophthalmology 3/2015

01.05.2015 | Clinical Investigation

Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals

verfasst von: Chiharu Iwahashi, Kensuke Okuno, Noriyasu Hashida, Kei Nakai, Nobuyuki Ohguro, Kohji Nishida

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Our aim was to determine the recurrence rate of inflammation in Vogt-Koyanagi-Harada (VKH) disease and to describe its clinical features.

Methods

We retrospectively evaluated patients diagnosed as having VKH disease with exudative retinal detachment at the Osaka University Hospital or the Japanese Community Healthcare Organization, Osaka Hospital, between 1998 and 2012. All patients received high-dose corticosteroid therapy as the initial treatment and were followed for at least 6 months. Demographic data, including age, sex, visual acuity (VA) levels at initial presentation and at 1 year after initial therapy, treatment received, and recurrent episodes were reviewed.

Results

Fifty-five consecutive patients with VKH disease were identified (36 women; mean age 38.6 ± 10.4 years). Fourteen patients (25.5 %) had recurrent inflammation, which manifested as posterior uveitis in eight and as anterior uveitis in six of the patients. Recurrent posterior segment inflammation was more likely to develop in patients whose VA at initial presentation was poor (P = 0.039) and in whom orally administered corticosteroid was tapered rapidly (to 30 mg within 3 weeks or less, to 20 mg within 2 months or less, and to 10 mg within 3 months or less) (P = 0.006, P = 0.066, and P = 0.041, respectively).

Conclusions

About 25 % of patients with VKH disease had recurrent inflammation. Poor initial VA and rapid tapering of the corticosteroid were associated with posterior recurrence.
Literatur
1.
Zurück zum Zitat Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. A prospective multi-center epidemiologic survey of uveitis in Japan: a 2009 survey. Jpn J Ophthalmol. 2012;56:432–5.CrossRefPubMed Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. A prospective multi-center epidemiologic survey of uveitis in Japan: a 2009 survey. Jpn J Ophthalmol. 2012;56:432–5.CrossRefPubMed
2.
Zurück zum Zitat Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosine family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000;165:7323–9.CrossRefPubMed Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosine family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000;165:7323–9.CrossRefPubMed
3.
Zurück zum Zitat Yamaki K, Kondo I, Nakamura H, Miyano M, Konno S, Sakuragi S. Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats. Exp Eye Res. 2000;71:361–9.CrossRefPubMed Yamaki K, Kondo I, Nakamura H, Miyano M, Konno S, Sakuragi S. Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats. Exp Eye Res. 2000;71:361–9.CrossRefPubMed
4.
Zurück zum Zitat Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39:265–92.CrossRefPubMed Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39:265–92.CrossRefPubMed
6.
Zurück zum Zitat Read RW, Rechodouni A, Butani N, Johnston R, Labree LD, Smith RE, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;31:599–606.CrossRef Read RW, Rechodouni A, Butani N, Johnston R, Labree LD, Smith RE, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;31:599–606.CrossRef
7.
Zurück zum Zitat Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada’s disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol. 1994;78:223–6.CrossRefPubMedCentralPubMed Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada’s disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol. 1994;78:223–6.CrossRefPubMedCentralPubMed
8.
Zurück zum Zitat Islam SM, Numaga J, Matsuki K, Fujino Y, Maeda H, Masuda K. Influence of HLA-DRB1 gene variation on the clinical course of Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994;35:752–6.PubMed Islam SM, Numaga J, Matsuki K, Fujino Y, Maeda H, Masuda K. Influence of HLA-DRB1 gene variation on the clinical course of Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994;35:752–6.PubMed
9.
Zurück zum Zitat Weisz JM, Holland GN, Roer LN, Park MS, Yuge AJ, Moorthy RS, et al. Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California. Ophthalmology. 1995;102:1012–5.CrossRefPubMed Weisz JM, Holland GN, Roer LN, Park MS, Yuge AJ, Moorthy RS, et al. Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California. Ophthalmology. 1995;102:1012–5.CrossRefPubMed
10.
Zurück zum Zitat Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647–52.CrossRefPubMed Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647–52.CrossRefPubMed
11.
Zurück zum Zitat Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317–23.CrossRefPubMed Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317–23.CrossRefPubMed
12.
Zurück zum Zitat Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Pohthalmol. 2008;126:1191–201.CrossRef Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Pohthalmol. 2008;126:1191–201.CrossRef
13.
Zurück zum Zitat Sachdev N, Gupta V, Gupta A, Singh R. Posterior segment recurrences in Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2008;28:339–45.CrossRefPubMed Sachdev N, Gupta V, Gupta A, Singh R. Posterior segment recurrences in Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2008;28:339–45.CrossRefPubMed
14.
Zurück zum Zitat Lai TY, Chan RP, Chan CK, Lam DS. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye. 2009;23:543–8.CrossRefPubMed Lai TY, Chan RP, Chan CK, Lam DS. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye. 2009;23:543–8.CrossRefPubMed
15.
Zurück zum Zitat Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome: clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682–7.CrossRefPubMed Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome: clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682–7.CrossRefPubMed
16.
Zurück zum Zitat Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D. Abu El-Asrar AM. Prognostic factors in Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27:201–10.CrossRefPubMed Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D. Abu El-Asrar AM. Prognostic factors in Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27:201–10.CrossRefPubMed
17.
Zurück zum Zitat Errera MH, Fardeau C, Cohen D, Navarro A, Gaudric A, Bodaghi B, et al. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2011;89:357–66.CrossRef Errera MH, Fardeau C, Cohen D, Navarro A, Gaudric A, Bodaghi B, et al. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2011;89:357–66.CrossRef
18.
Zurück zum Zitat Bacsal K, Wen DS, Chee SP. Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2008;145:480–6.CrossRefPubMed Bacsal K, Wen DS, Chee SP. Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2008;145:480–6.CrossRefPubMed
19.
Zurück zum Zitat Taylor S, Lightman S. Recurrent anterior uveitis in patients with Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol. 2004;122:922–3.CrossRefPubMed Taylor S, Lightman S. Recurrent anterior uveitis in patients with Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol. 2004;122:922–3.CrossRefPubMed
20.
Zurück zum Zitat Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.CrossRefPubMed Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.CrossRefPubMed
21.
Zurück zum Zitat Kondo Y, Fukuda K, Suzuki K, Nishida T. Chronic noninfectious uveitis associated with Vogt-Koyanagi-Harada disease treated with low-dose weekly systemic methotrexate. Jpn J Ophthalmol. 2012;56:104–6.CrossRefPubMed Kondo Y, Fukuda K, Suzuki K, Nishida T. Chronic noninfectious uveitis associated with Vogt-Koyanagi-Harada disease treated with low-dose weekly systemic methotrexate. Jpn J Ophthalmol. 2012;56:104–6.CrossRefPubMed
22.
Zurück zum Zitat Liu X, Yang P, Lin X, Ren X, Zhou H, Huang X, et al. Inhibitory effect of cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin Immunol. 2009;131:333–42.CrossRefPubMed Liu X, Yang P, Lin X, Ren X, Zhou H, Huang X, et al. Inhibitory effect of cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin Immunol. 2009;131:333–42.CrossRefPubMed
23.
Zurück zum Zitat Nakao K, Abematsu N, Mizushima Y, Sakamoto T. Optic disc swelling in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2012;53:1917–22.CrossRefPubMed Nakao K, Abematsu N, Mizushima Y, Sakamoto T. Optic disc swelling in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2012;53:1917–22.CrossRefPubMed
Metadaten
Titel
Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals
verfasst von
Chiharu Iwahashi
Kensuke Okuno
Noriyasu Hashida
Kei Nakai
Nobuyuki Ohguro
Kohji Nishida
Publikationsdatum
01.05.2015
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 3/2015
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-015-0377-1

Weitere Artikel der Ausgabe 3/2015

Japanese Journal of Ophthalmology 3/2015 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.